Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP / Martinelli, G; Castagnetti, F; Poerio, A; Breccia, M; Palandri, F; Alimena, G; Pane, F; Saglio, G; Baccarani, M; Rosti, G. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 27:15(2009). (Intervento presentato al convegno ASCO).
Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP
Breccia M;
2009
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
